Venetoclax in combination with bortezomib and dexamethasone significantly improved progression-free survival (PFS) and response rates in the BELLINI trial in patients with relapsed/refractory (R/R) multiple myeloma (MM), with even greater benefits seen in patients with t(11;14) translocation or high BCL2 gene expression.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Denosumab bests zoledronic acid at preventing skeletal-related events in vulnerable cancer patients, according to the results of a meta-analysis. The former also shows a better tolerability profile despite being associated with potential yet manageable adverse events.
Comprehensive recommendations on coronavirus disease 2019 (COVID-19) for cancer patients have become available following review of guidelines from 63 national/international oncology societies. [Lancet Oncol 2020, doi: 10.1016/S1470-2045(20)30278-3]
New drug applications approved by US FDA as of 01 - 15 May 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Once-weekly treatment with carfilzomib at the higher 70-mg/m2 dose appears to improve survival in patients with relapsed and refractory multiple myeloma (RRMM) compared with the twice-weekly 27-mg/m2 dosing regimen, regardless of patient and disease characteristics, according to data from the phase III ARROW study.
Liquid biopsy may facilitate detection and serial monitoring of multidrug resistance (MDR) in multiple myeloma by analysing multiparticles (MPs) in blood samples of patients, with a recent study showing that MDR markers are found on MPs of stem-cell-like origin.
The once-weekly carfilzomib regimen of Kd70 mg/m2 for relapsed or refractory multiple myeloma (RRMM) is more favourable than the twice-weekly Kd27 mg/m2, as the former is associated with delayed symptom worsening and greater patient-reported convenience and satisfaction, according to a recent study.
The addition of daratumumab (D) to a bortezomib, melphalan, and prednisone (VMP) regimen improved overall survival (OS) in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplantation (ASCT), results of the phase III ALCYONE trial showed.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).